Flowbone ^Company

Flowbone is addressing the challenges of osteoporosis, a condition affecting 250 million people worldwide, leading to increased fracture risk. To fill the treatment gap for patients at high fracture risk, Flowbone has developed an innovative injectable gel that strengthens fragile bones locally. This unique gel kickstarts the body's mineral deposition process, quickly transforming into strong, viable bone without interfering with vascularization and biomechanics. Flowbone, established in 2020 as an EPFL spin-off, envisions a world where the elderly can enjoy independence and quality of life, free from the impact of fragility fractures. While their products are still in development and not yet available, Flowbone's mission is focused on enhancing the well-being of aging individuals.